Results 141 to 150 of about 45,703 (244)

An Overview of Liquid Chromatography–Mass Spectrometry (LC–MS) Methods for the Quantification of Antibody‐Drug Conjugates

Biomedical Chromatography, Volume 40, Issue 2, February 2026.
ABSTRACT Antibody‐drug conjugates (ADCs) are innovative drugs composed of cytotoxic molecules (payload) linked to antibodies, that selectively target and kill cancer cells upon internalization. In vivo, ADCs exist as intact molecules, naked antibodies, or released, unconjugated (linker‐)payload.
Pauline L. M. Buitelaar, Hilde Rosing, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema   +4 more
wiley   +1 more source

ADCC Assay [PDF]

, 2020
openaire   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

Gene Regulatory Programs of NK Cells Show That NCAM1 (CD56) and KIRs Are Controlled by Genetically Polymorphic Distal Regulatory Elements

European Journal of Immunology, Volume 56, Issue 2, February 2026.
A deeper understanding of the natural killer cell gene expression regulation driving NK cell maturation and cytotoxicity could provide critical insights into optimizing NK therapies. Our findings reveal novel enhancers governing NK cell genes for NCAM1/CD56 and cis‐regulation for KIR receptors and clarify existing models of NK cell cis‐accessibility ...
Mariam A. Salem, Aditi Varkey, Matthew D. Estrada, Kruthika Sharma, Caprice D. Eisele, Nitin Chakravarti, Dean A. Lee, Aharon G. Freud, Bethany L. Mundy‐Bosse, Patrick L. Collins   +9 more
wiley   +1 more source

Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Polatuzumab vedotin (Pola) is an antibody‐drug conjugate approved for the treatment of diffuse large B‐cell lymphoma (DLBCL). Several reports suggest that the tumor microenvironment influences the outcome of DLBCL treatments; with Pola, however, the link between tumor microenvironment and treatment outcome remains unclear ...
Mayu Tomita, Natsumi Kawasaki, Keigo Yorozu, Sei Shu, Chie Kato, Mitsue Kurasawa, Bansho Masutani, Nicolas Sax, Yoriko Yamashita‐Kashima, Shigeki Yoshiura   +9 more
wiley   +1 more source

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source

[Corrigendum] Role of hypoxia‑inducible factor‑1α and CD146 in epidermal growth factor receptor‑mediated angiogenesis in salivary gland adenoid cystic carcinoma [PDF]

Mol Med Rep
Wang WM, Zhao ZL, Zhang WF, Zhao YF, Zhang L, Sun ZJ.   +5 more
europepmc   +1 more source

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings, Serbülent Ünsal, Mathieu Rappas, Matthew Barnes, Maria Waldhoer, Ben Holland, Martin Culka   +6 more
wiley   +1 more source

A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers. [PDF]

ESMO Open
Alfieri S, Rota S, Romanò R, Capone I, Busico A, Conca E, Tamborini E, Cavalieri S, Buriolla S, Sciortino C, Leone AG, Nuzzolese I, Ottini A, Bergamini C, Quattrone P, Vingiani A, Locati LD, Licitra L, Pruneri G, Colombo E, Agnelli L, Perrone F.   +21 more
europepmc   +1 more source

Treatment‐Related and Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitor‐Based Combination Therapies for Breast Cancer: A Systematic Review and Meta‐Analysis

Thoracic Cancer, Volume 17, Issue 3, February 2026.
This systematic review and meta‐analysis (100 trials, 9192 patients) clarifies breast cancer ICI‐based combination toxicity hierarchies. ICI‐ADC has higher grade ≥ 3 TRAEs; ICI‐mTKI has the worst irAEs, while ICI‐PARPi/HER2‐targeted combinations present the lowest risks.
Yunwei Lu, Huan Li, Ke Li, Yiting Chen, Shu Wang   +4 more
wiley   +1 more source